NCT04315298View on ClinicalTrials.gov

Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

1,912

Participants

Timeline

Start Date

March 18, 2020

Primary Completion Date

July 24, 2020

Study Completion Date

September 2, 2020

Conditions
COVID-19
Interventions
DRUG

Sarilumab

Single or multiple intravenous (IV) doses of sarilumab. Additional doses may be administered if the patient meets protocol defined criteria.

DRUG

Placebo

Single or multiple intravenous (IV) doses of placebo to match sarilumab administration

Trial Locations (62)

10003

Regeneron Study Site, New York

10016

Regeneron Study Site, New York

10025

Regeneron Study Site 1, New York

Regeneron Study Site 2, New York

10029

Regeneron Study Site, New York

10032

Regeneron Study Site, New York

10037

Regeneron Study Site, New York

10065

Regeneron Study Site, New York

10075

Regeneron Study Site, New York

10451

Regeneron Study Site, The Bronx

10461

Regeneron Study Site 1, The Bronx

Regeneron Study Site 2, The Bronx

10467

Regeneron Study Site, The Bronx

10595

Regeneron Study Site, Valhalla

11030

Regeneron Study Site 1, Manhasset

Regeneron Study Site 2, Manhasset

11219

Regeneron Study Site, Brooklyn

11373

Regeneron Study Site, Elmhurst

11794

Regeneron Study Site, Stony Brook

14263

Regeneron Study Site, Buffalo

17822

Regeneron Study Site, Danville

18510

Regeneron Study Site, Scranton

18711

Regeneron Study Site, Wilkes-Barre

19140

Regeneron Study Site, Philadelphia

20010

Regeneron Study Site, Washington D.C.

22042

Regeneron Study Site, Falls Church

23298

Regeneron Study Site, Richmond

30033

Regeneron Study Site, Decatur

30060

Regeneron Study Site, Marietta

30322

Regeneron Study Site, Atlanta

32610

Regeneron Study Site, Gainesville

32803

Regeneron Study Site, Orlando

33606

Regeneron Study Site, Tampa

48109

Regeneron Study Site, Ann Arbor

55905

Regeneron Study Site, Rochester

60611

Regeneron Study Site, Chicago

60612

Regeneron Study Site, Chicago

70112

Regeneron Study Site, New Orleans

74104

Regeneron Study Site, Tulsa

75246

Regeneron Study Site, Dallas

75390

Regeneron Study Site, Dallas

80045

Regeneron Study Site, Aurora

80206

Regeneron Study Site, Denver

84107

Regeneron Study Site, Murray

90095

Regeneron Study Site, Los Angeles

90404

Regeneron Study Site, Santa Monica

95817

Regeneron Study Site, Sacramento

97213

Regeneron Study Site, Portland

97239

Regeneron Study Site, Portland

98055

Regeneron Study Site, Renton

98201

Regeneron Study Site, Everett

06520

Regeneron Study Site, New Haven

02111

Regeneron Study Site, Boston

02114

Regeneron Study Site, Boston

02215

Regeneron Study Site, Boston

08820

Regeneron Study Site, Edison

07601

Regeneron Study Site, Hackensack

07039

Regeneron Study Site, Livingston

07960

Regeneron Study Site, Morristown

07753

Regeneron Study Site, Neptune City

07112

Regeneron Study Site, Newark

07666

Regeneron Study Site, Teaneck

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Regeneron Pharmaceuticals

INDUSTRY

NCT04315298 - Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 | Biotech Hunter | Biotech Hunter